BIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC) Files An 8-K Regulation FD Disclosure

ME Staff 8-k

5 years ago

BIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD

On October 23, 2019, the Company issued a press release announcing that on October 21, 2019, the Board of Directors (the Board) of the Company elected Jennifer Chao to serve as the chairperson of the Board, effective immediately. Ms. Chao has served on the Board as an independent director since 2015. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

(d) Exhibits

99.1

Press Release dated October 23, 2019

BIOSPECIFICS TECHNOLOGIES CORP Exhibit
EX-99.1 2 d821010dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Jennifer Chao Appointed Chairperson of BioSpecifics Technologies Corp. Board of Directors LYNBROOK,…
To view the full exhibit click here

About BIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC)

BioSpecifics Technologies Corp. (BioSpecifics) is a biopharmaceutical company. The Company is engaged in the development of an injectable collagenase clostridium histolyticum (CCH) for multiple indications. The Company has a development and license agreement with Endo International plc (Endo) for injectable collagenases for marketed indications and indications in development. CCH is marketed as XIAFLEX and as XIAPEX in Europe. Its injectable collagenases are marketed for indications, such as Dupuytren’s contracture and Peyronie’s disease. BioSpecifics is conducting development work with respect to human lipoma and uterine fibroids. XIAFLEX and XIAPEX are approved in the United States, the European Union, Switzerland, Canada, Australia and Japan for the treatment of Dupuytren’s contracture. Endo manages the research and development of XIAFLEX for their licensed indications, including frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis and uterine fibroids.